combination therapy with glp-1 receptor agonist and sglt2 inhibitor Agonists Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined | Drugs Perspectives in weight control in
Description
There are ongoing studies including a large phase 3 trial underway to determine if semaglutide will meet any of these clinical endpoints for FDA approval
AE, adverse event
Researchers who study the pancreatic peptide hormone system will recognize glucagon as the metabolic counterweight to insulin, and harnessing it pharmacologically opens therapeutic possibilities that the research community has pursued for decades
In a Phase III trial targeting people with obesity but not diabetes, Novo aimed for 25% weight loss a goal it missed in December
